NeOnc Technologies Holdings, Inc. announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO212, an orally administered perillyl alcohol-temozolomide carbamate conjugate for treating aggressive brain tumors. NeOnc Technologies Holdings, Inc. is a biotechnology company developing therapeutic solutions for oncology.
